drugset / Trial / NCT01607554
Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer
Phase 1/2
Terminated
2 enrolled
New Mexico Cancer Research Alliance
Lovelace Respiratory Research Institute · collabUniversity of New Mexico Cancer Center · collab
NaSingle-groupOpen-labelTreatment
Summary
Certain genetic factors can affect a patient's potential sensitivity to therapeutic drugs and other agents. There is a factor called ISG15 which might help doctors better identify patients with advanced non-small cell lung cancer (NSCLC) whose tumors may be more sensitive to the drug called Irinotecan. This factor is elevated in roughly 30% of NSCLC cases. Irinotecan is an agent that inhibits the enzyme called topoisomerase I that is involved in cell growth, and it has been FDA approved for 17 years for another type of cancer.
Timeline
- Start
- 2012-04
- Primary completion
- 2013-03
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |